Use of fibrates in diabetes: what does the FIELD trial tell us?

FIELD was the largest cardiovascular prevention trial using fibrates in type 2 diabetes. Whilst the primary endpoint was not achieved, fenofibrate therapy associated with fewer non‐fatal myocardial infarctions and revascularisation procedures. Progress of renal and retinal microvascular disease appe...

Full description

Saved in:
Bibliographic Details
Published in:Practical diabetes international 2006-04, Vol.23 (3), p.135-137
Main Author: Jowett, NI
Format: Article
Language:English
Subjects:
coronary heart disease
dyslipidaemia
fibrates
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FIELD was the largest cardiovascular prevention trial using fibrates in type 2 diabetes. Whilst the primary endpoint was not achieved, fenofibrate therapy associated with fewer non‐fatal myocardial infarctions and revascularisation procedures. Progress of renal and retinal microvascular disease appeared to be slowed. Although many patients were also taking statin therapy, FIELD does not provide evidence on efficacy or long‐term safety when co‐prescribed with fibrates. Statin monotherapy remains first line therapy for diabetic dyslipidaemia. Copyright © 2006 John Wiley & Sons, Ltd.
ISSN:1357-8170
1528-252X
DOI:10.1002/pdi.921